Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CarboRaft is an oral therapeutic combination developed by ARB Remedies, consisting of sodium alginate, sodium bicarbonate, and calcium carbonate. It is indicated for the symptomatic relief of heartburn, indigestion, and acid reflux. The mechanism of action involves a dual approach: the sodium alginate reacts with gastric acid to form a viscous, pH-neutral gel raft that floats on the stomach contents, physically obstructing the reflux of acid into the esophagus. Concurrently, the bicarbonate and carbonate salts act as antacids, neutralizing excess gastric acid to alleviate irritation of the gastrointestinal mucosa. This combination is typically administered as an oral suspension to provide rapid and sustained relief from symptoms of gastroesophageal reflux.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CarboRaft.